Results 151 to 160 of about 100,757 (302)

Commentary on Borodovsky et al.: Enhancing research on THC quantification—Consumer awareness through accurate labelling

Addiction, Volume 120, Issue 4, Page 686-687, April 2025.
Rachel Lees Thorne, Tom P. Freeman
wiley   +1 more source

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, EarlyView.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

Consumption Patterns of Psychotropic Drugs Among Veterinary Medicine Students at the Federal University of Santa Maria. [PDF]

Int J Environ Res Public Health
Silva Pereira GJ, Arboit F, Diniz JR, Zanchet EM, Bochi GV.   +4 more
europepmc   +1 more source

Diagnostic validity of Addictions Neuroclinical Assessment indices for alcohol use disorder: Findings from an observational case–control study

Addiction, EarlyView.
Abstract Background and aims The Addictions Neuroclinical Assessment (ANA) provides a framework for assessing alcohol use disorder (AUD) with indices that may be both mechanistically and diagnostically informative. This study evaluated an array of measures from the three ANA domains in relation to AUD diagnostic status. Design This cross‐sectional case–
Molly L. Garber, Carly McIntyre‐Wood, Mahmoud Elsayed, Michael T. Amlung, Lawrence H. Sweet, James MacKillop   +5 more
wiley   +1 more source

Temporal and geographical patterns of nitazene detections in drug samples and biospecimens in the United States, 2019–2024

Addiction, EarlyView.
Abstract Background and aims Nitazenes are a novel subclass of synthetic opioids that have been increasingly implicated in the United States (US) overdose crisis. Despite their growing presence in the illicit drug supply, national trends have not been systematically evaluated.
David T. Zhu, Nicole D. Fitzgerald, Joseph J. Palamar, Alex J. Krotulski   +3 more
wiley   +1 more source

Evaluating and Determining the Effects of Psychotropic Drugs on Motor Vehicle Driving Performance: Key Considerations of the Japanese Guideline and Criteria for Clinical Implementation of Evidence. [PDF]

Neuropsychopharmacol Rep
Nakabayashi T, Iwamoto K, Yamaguchi A, Konishi Y, Saji M, Yoshimura R, Kanemoto K, Aoki H, Ando M, Ozaki N.   +9 more
europepmc   +1 more source

Regional perspectives: Substance use related problems in Ethiopia

Addiction, EarlyView.
Abstract Ethiopia, with a population exceeding 130 million, presents a complex landscape for understanding substance use disorders. The country's diverse cultural heritage, varying regional practices, and evolving socioeconomic conditions create unique factors of substance use that differ markedly from global trends.
Tesfa M. Yimer, Wubalem Fekadu, Janni Leung, Awoke Mihretu, Solomon Teferra   +4 more
wiley   +1 more source

Therapeutic Drug Monitoring of Psychotropic Drugs in Inpatient Psychiatry: Local Practice and Improvement. [PDF]

Psychiatry Clin Psychopharmacol
Pfeifer P, Mathys B, Alan EM, Bracht T, Choinowski S, Adorjan K, Klöppel S.   +6 more
europepmc   +1 more source

A drug education manual concerning illicit drugs and psychotropics - For teachers in secondary schools in the Member States of the European Community. Medicine. EUR 10594 EN [PDF]

, 1986
Basso, F., Casselman, J., Moorthamer, L., Van Hende, L.   +3 more
core  

What anabolic–androgenic steroids reveal about the limits of current harm reduction models

Addiction, EarlyView.
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski, Jason M. Nagata, Suzanne Nielsen   +2 more
wiley   +1 more source